

Table 5: **Protease**

MAB ID	HXB2 Location	Author's Location	Sequence	Neutral-izing	Immunogen	Species (Isotype)
162 1696	Protease(1–7)	Pro(1–7 BH10)	PQIYLWQ		Vaccine	murine(IgG)
<b>Vaccine:</b> <i>Vector/type:</i> protein <i>HIV component:</i> Protease <b>Ab type:</b> N-term <b>References:</b> [Lescar (1999)] <ul style="list-style-type: none"> <li>1696: MAb binds to HIV-1 and HIV-2, putative epitopes are PQIYLWQ and PQFSLWK respectively – Pro1 is critical, QIYLWQR residues 2–8 do not compete without it – MAb disrupts catalytic activity – crystal structure of Fab at 3 Å resolution reveals a deep cavity lined by acidic and hydrophobic residues – the binding region is located within the region required for dimerization and the Fab structure could serve as a basis for drug design targeting this region [Lescar (1999)]</li> </ul>						
163 10E7	Protease(36–46)	Pro(38–45 HXB2)	MSLPGRWKPKM	no	Vaccine	hamster(IgG)
<b>Vaccine:</b> <i>Vector/type:</i> recombinant protein <i>HIV component:</i> Protease <b>References:</b> [Croix (1993)] <ul style="list-style-type: none"> <li>10E7: Immunodominant region of protease in Armenian hamster (but only weakly reactive in people, see: [Bjorling1992]) – peptide MSLPGRWKP blocks protease binding [Croix (1993)]</li> </ul>						
164 F11.2.32	Protease(36–46)	Pro(36–46 BH10)	MSLPGRWKPKM		Vaccine	murine(IgG1 $\kappa$ )
<b>Vaccine:</b> <i>Vector/type:</i> recombinant protein <i>Strain:</i> BH10 <i>HIV component:</i> Protease <b>Ab type:</b> flap region <b>References:</b> [Lescar (1996), Lescar (1997), Lescar (1999)] <ul style="list-style-type: none"> <li>F11.2.32: Binding leads to significant inhibition in proteolytic activity – crystal structure of Fab-peptide was determined to 2.2 Å resolution – bound peptide shows no structural similarity to the corresponding segment in native protease suggesting binding may distort protein structure [Lescar (1997)]</li> <li>F11.2.32: Distortion may occur in the flap region of the protein, important for regulating access of substrate to the catalytic site [Lescar (1999)]</li> </ul>						
165 13E1	Protease(38–45)	Pro(38–45 HXB2)	LPGRWKPK	no	Vaccine	hamster(IgG)
<b>Vaccine:</b> <i>Vector/type:</i> recombinant protein <i>HIV component:</i> Protease <b>References:</b> [Croix (1993)] <ul style="list-style-type: none"> <li>13E1: LPGRWKPK is the core of the epitope – binds to MSLPGRWKPKM with slightly higher affinity [Croix (1993)]</li> </ul>						
166 8B11	Protease(38–45)	Pro(38–45 HXB2)	LPGRWKPK	no	Vaccine	hamster(IgG)
<b>Vaccine:</b> <i>Vector/type:</i> recombinant protein <i>HIV component:</i> Protease <b>References:</b> [Croix (1993)] <ul style="list-style-type: none"> <li>8B11: LPGRWKPK is the core of the epitope – binds to MSLPGRWKPKM with slightly higher affinity [Croix (1993)]</li> </ul>						

# Table of HIV MAbs

167	8C10	Protease(38–45)	Pro(38–45 HXB2)	LPGRWKPK	no Vaccine	hamster(IgG)
<b>Vaccine:</b> <i>Vector/type:</i> recombinant protein <i>HIV component:</i> Protease <b>References:</b> [Croix (1993)] • 8C10: LPGRWKPK is the core of the eptiope – binds to MSLPGRWKPKM with sightly higher affinity [Croix (1993)]						
168	8G5	Protease(38–45)	Pro(38–45 HXB2)	LPGRWKPK	no Vaccine	hamster(IgG)
<b>Vaccine:</b> <i>Vector/type:</i> recombinant protein <i>HIV component:</i> Protease <b>References:</b> [Croix (1993)] • 8G5: LPGRWKPK is the core of the eptiope – binds to MSLPGRWKPKM with sightly higher affinity [Croix (1993)]						